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INTRODUCTION: 
Fibrillar collagens are rich in the amino acid hydroxy 
proline, which is excreted in the urine after collagen 
degradation and are considered to be markers of bone 
resorption. The urinary excretion of hydroxy proline is 
increased in states of physiologically high turnover, 
such as somatic growth, during menopause and high 
turnover osteopathies
1
.This increased excretion is due 
to increase in bone loss which was a characteristic 
feature of the postmenopausal period. 
Estrogen deficiency at the menopause increases the 
rate of bone remodelling, which results in high 
turnover bone loss. There are recognized receptors on 
the osteoblast which do not function optimally due to 
lack of Estrogen. This is reflected by a significant 
increase in the mean value of markers of resorption  
from premenopause to postmenopause
2
. Thus simple, 
direct urinary assay of hydroxy proline to measure 
bone resorption have clinical applications as part of 
screening programs to assess the risk of osteoporotic 
fractures. 
Aim:To estimate urinary hydroxy- proline in pre and 
post menopausal  Women as a marker of bone 
resorption. 
MATERIALS AND METHODS:  
This is a prospective observational study conducted at 
Gandhi hospital, during the period between June 2008 
to June 2010. 25 healthy post menopausal women were 
selected as cases and 25 healthy pre menopausal 
women were selected as controls. 
Inclusion criteria wasHealthy women who had ceased 
menstruation for 3 to 5 years and not started taking 
hormone replacement therapy, non obese  and without 
regular use of calcium supplementations or any other 
medications known to affect bone metabolism was 
selected as cases. 25 healthy women in the age group 
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of 30-40 years who were regularly menstruating and 
not pregnant and not on oral contraceptives were 
selected as controls. 
Exclusion criteria is Women with history of known 
osteoporotic fractures, diabetes mellitus, renal failure, 
major liver diseases or those on hormone replacement 
therapy and oral corticosteroid were excluded from the 
study among both cases and controls. 
Urinary hydroxy proline was estimated after collecting 
24 hours urine by calorimetric technique using the 
Modified Neuman and Logan method
3,4
. All the 
reagents used in the estimation were of analytical 
grade. 
RESULT:  
The age distributions among cases were between 50- 
71years with mean of 54.84 ±6.1in the menopausal 
women. In controls (pre menopausal ) women age was 
between 21-41 with the mean of 31.96 ±7.1. The mean 
urinary hydroxy proline excreted in cases (Post 
menopausal women)   was 31.64mg/24hrs with 
standard deviation of 3.37. The mean urinary hydroxy 
proline in controls  was19.61mg/24hrs with standard 
deviation of 2.34.It has got statistical significance with 
p value of < 0.0001.Hydroxy proline excretion in urine 
was positively correlated with age. This correlation is 
statistically significant with p value of < 0.01. 
DISCUSSION:  
Osteoporosis leads to considerable morbidity and 
mortality in postmenopausal women. The mean age at 
menopause was observed to be 49.66 years
5
. Bone 
mass decreases with ageing, and it is now well 
established that a low bone mass is the major 
determinant of all osteoporotic fractures. The dramatic 
increase in the bone turnover rate with an imbalance 
between bone formation and bone resorption in the 
first year after the cessation of ovarian function is 
responsible for the accelerated rate of postmenopausal 
bone loss. High bone turnover rate seems to play an 
increasing role as a determinant of bone mass with 
increasing postmenopausal age.As Hydroxy proline 
forms 16% of bone matrix, the increase in bone 
turnover after menopause will show increase in urinary 
excretion of Hydroxy proline which is proved in our 
study and consistent with other studies.
6,7 
CONCLUSION: 
Osteoporosis is a systemic skeletal disease 
characterized by low bone mass and micro-
architectural deterioration of bone 
tissue.Postmenopausal women are more prone for 
osteoporosis. In our study Urinary hydroxy proline 
level was increased in post menopausal women when 
compared to premenopausal women. We conclude that 
Urinary Hydroxy proline estimation is cheap 
biochemical marker to detect osteoporosis in post 
menopausal women 
Table showing urinary levels of Hydroxy proline in 
Post & Pre Menopausal women 
 
Sl.No Cases Controls 
1 28.70 19.70 
2 23.60 20.78 
3 38.50 21.10 
4 33.50 20.52 
5 27.08 16.87 
6 30.32 19.28 
7 28.80 20.08 
8 35.21 17.14 
9 30.43 17.89 
10 33.69 24.10 
11 33.50 18.64 
12 33.00 18.85 
13 32.67 16.71 
14 34.60 17.67 
15 31.85 16.92 
16 33.20 26.25 
17 30.65 17.41 
18 31.52 17.67 
19 32.00 21.53 
20 30.52 20.89 
21 25.08 18.21 
22 33.04 18.96 
23 31.08 21.96 
24 37.50 21.53 
25 31.08 19.73 
Total 791.12 490.39 
Mean 31.64 19.61 
S.D 3.37 2.34 
p. value <0.0001 
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